Literature DB >> 4142955

Reserpine and breast cancer.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4142955

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

Review 1.  [Reserpine-diuretic combinations in therapy of arterial hypertension. Current considerations].

Authors:  M Siepmann; W Kirch
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  Data mining in pharmacovigilance: lessons from phantom ships.

Authors:  Manfred Hauben; Lester Reich; Eugène P Van Puijenbroek; Charles M Gerrits; Vaishali K Patadia
Journal:  Eur J Clin Pharmacol       Date:  2006-08-03       Impact factor: 2.953

Review 3.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

Review 4.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

Review 5.  Carcinogenicity of antihypertensive therapy.

Authors:  Ehud Grossman; Franz H Messerli; Uri Goldbourt
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 6.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

Review 7.  Can we justify goal blood pressure of <140/90 mm Hg in most hypertensives?

Authors:  Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

8.  Prolactin secretion during reserpine and syrosingopine treatment.

Authors:  E Camanni; E Strumia; P Portaleone; G M Molinatti
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.

Authors:  Isla S Mackenzie; Steven V Morant; Li Wei; Alastair M Thompson; Thomas M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2016-11-12       Impact factor: 4.335

10.  Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.

Authors:  Isla S Mackenzie; Thomas M Macdonald; Alastair Thompson; Steve Morant; Li Wei
Journal:  BMJ       Date:  2012-07-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.